Nephrotoxicity risks of colistin-combination therapy: a USFDA adverse event reporting system analysis using disproportionality and interaction assessment
Colistin combinations with certain antimicrobials, especially ceftazidime, vancomycin, and tigecycline, carry significantly higher nephrotoxicity risks, warranting careful clinical consideration. Rigorous renal monitoring protocols are essential in managing these therapies, particularly in critically ill patients.
Authors
- Kannan Sridharan (ORCID: https://orcid.org/0000-0003-3811-6503)
Institutions
- Arabian Gulf University (BH)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1080/14740338.2025.2499672
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00